John Mendelsohn, MD
MD Anderson Cancer Center
The University of Texas
Dr. Mendelsohn has been at the forefront in understanding how growth factors regulate the proliferation of cancer cells by activating receptors that control key cell signaling pathways. He and his research team pioneered the concept of targeted anti-receptor therapy as a new form of cancer treatment. In addition, Dr. Mendelsohn discovered that blocking epidermal growth factor (EGF) receptor activity could reverse resistance to chemotherapy. He and collaborators developed the monoclonal antibody 225 (cetuximab), which blocks EGF binding, and which was FDA approved for colon cancer in 2004 and for head and neck cancer in 2006.
Targeting the EGF Receptor for Cancer Therapy